Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study.

IF 1.8 Q3 PERIPHERAL VASCULAR DISEASE

Stroke Research and Treatment Pub Date : 2018-10-03 eCollection Date: 2018-01-01 DOI:10.1155/2018/7532403

Ilaria Maestrini, Marta Altieri, Laura Di Clemente, Edoardo Vicenzini, Patrizia Pantano, Eytan Raz, Mauro Silvestrini, Leandro Provinciali, Isabella Paolino, Carmine Marini, Matteo Di Giuseppe, Tommasina Russo, Francesco Federico, Cristiana Coppola, Maria Pia Prontera, Domenico Maria Mezzapesa, Vincenzo Lucivero, Lucilla Parnetti, Paola Sarchielli, Maria Peducci, Domenico Inzitari, Giovanna Carlucci, Carlo Serrati, Carla Zat, Anna Cavallini, Alessandra Persico, Giuseppe Micieli, Stefano Bastianello, Vittorio Di Piero

{"title":"Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study.","authors":"Ilaria Maestrini, Marta Altieri, Laura Di Clemente, Edoardo Vicenzini, Patrizia Pantano, Eytan Raz, Mauro Silvestrini, Leandro Provinciali, Isabella Paolino, Carmine Marini, Matteo Di Giuseppe, Tommasina Russo, Francesco Federico, Cristiana Coppola, Maria Pia Prontera, Domenico Maria Mezzapesa, Vincenzo Lucivero, Lucilla Parnetti, Paola Sarchielli, Maria Peducci, Domenico Inzitari, Giovanna Carlucci, Carlo Serrati, Carla Zat, Anna Cavallini, Alessandra Persico, Giuseppe Micieli, Stefano Bastianello, Vittorio Di Piero","doi":"10.1155/2018/7532403","DOIUrl":null,"url":null,"abstract":"Background: We investigated low-dose aspirin (ASA) efficacy and safety in subjects with silent brain infarcts (SBIs) in preventing new cerebrovascular (CVD) events as well as cognitive impairment.Methods: We included subjects aged ≥45 years, with at least one SBI and no previous CVD. Subjects were followed up to 4 years assessing CVD and SBI incidence as primary endpoint and as secondary endpoints: (a) cardiovascular and adverse events and (b) cognitive impairment.Results: Thirty-six subjects received ASA while 47 were untreated. Primary endpoint occurred in 9 controls (19.1%) versus 2 (5.6%) in the ASA group (p=0.10). Secondary endpoints did not differ in the two groups. Only baseline leukoaraiosis predicts primary [OR 5.4 (95%CI 1.3-22.9, p=0.022)] and secondary endpoint-a [3.2 (95%CI 1.1-9.6, p=0.040)] occurrence.Conclusions: These data show an increase of new CVD events in the untreated group. Despite the study limitations, SBI seems to be a negative prognostic factor and ASA preventive treatment might improve SBI prognosis. EU Clinical trial is registered with EudraCT Number: 2005-000996-16; Sponsor Protocol Number: 694/30.06.04.","PeriodicalId":22054,"journal":{"name":"Stroke Research and Treatment","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2018-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/7532403","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/7532403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 15

Abstract

Background: We investigated low-dose aspirin (ASA) efficacy and safety in subjects with silent brain infarcts (SBIs) in preventing new cerebrovascular (CVD) events as well as cognitive impairment.

Methods: We included subjects aged ≥45 years, with at least one SBI and no previous CVD. Subjects were followed up to 4 years assessing CVD and SBI incidence as primary endpoint and as secondary endpoints: (a) cardiovascular and adverse events and (b) cognitive impairment.

Results: Thirty-six subjects received ASA while 47 were untreated. Primary endpoint occurred in 9 controls (19.1%) versus 2 (5.6%) in the ASA group (p=0.10). Secondary endpoints did not differ in the two groups. Only baseline leukoaraiosis predicts primary [OR 5.4 (95%CI 1.3-22.9, p=0.022)] and secondary endpoint-a [3.2 (95%CI 1.1-9.6, p=0.040)] occurrence.

Conclusions: These data show an increase of new CVD events in the untreated group. Despite the study limitations, SBI seems to be a negative prognostic factor and ASA preventive treatment might improve SBI prognosis. EU Clinical trial is registered with EudraCT Number: 2005-000996-16; Sponsor Protocol Number: 694/30.06.04.

查看原文本刊更多论文

低剂量阿司匹林与安慰剂治疗无症状脑梗死的纵向研究:无症状研究

背景:我们研究了低剂量阿司匹林(ASA)在无症状脑梗死(sbi)患者中预防新发脑血管(CVD)事件和认知障碍的有效性和安全性。方法:我们纳入了年龄≥45岁、至少有一次SBI且既往无CVD的受试者。受试者随访4年，评估CVD和SBI发生率作为主要终点和次要终点:(a)心血管和不良事件，(b)认知障碍。结果:ASA治疗组36例，未治疗组47例。主要终点发生在9个对照组(19.1%)，而ASA组有2个(5.6%)(p=0.10)。两组的次要终点无差异。只有基线白质病变预测原发性[OR 5.4 (95%CI 1.3-22.9, p=0.022)]和继发性终点a [3.2 (95%CI 1.1-9.6, p=0.040)]的发生。结论:这些数据显示未治疗组新的CVD事件增加。尽管研究存在局限性，但SBI似乎是一个负面预后因素，ASA预防性治疗可能改善SBI预后。欧盟临床试验注册编号:2005-000996-16;赞助协议号:694/30.06.04。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stroke Research and Treatment PERIPHERAL VASCULAR DISEASE-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

12 weeks